Business
Beam Therapeutics to Participate in Upcoming September Investor Conferences
CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines
About this update from Beam Therapeutics Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following September investor conferences: Citi’s 18th Annual BioPharma Conference 2023 on Thursday, September 7, 2023 at 8:50 a.m. ET in Boston;2023 Wells Fargo Securities Healthcare Conference on Thursday, September 7, 2023 at 10:15 a.m. ET in Boston; and,BMO BioPharma Virtual Spotlight Series: Gene Editing and Therapy on Tuesday, September 26, 2023 at 10:00 a.m. ET. Live webcasts will be available in the investor section of the company's website at www.beamtx.com, and will be archived for 60 days following the presentation. About Beam TherapeuticsBeam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a suite of gene editing and delivery technologies and is in the process of building internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. Contacts: Investors:Holly ManningTHRUST Strategic [email protected] Media:Dan [email protected] \nSource: Beam Therapeutics","length":3846,"tagName":"div"}]